Integrated BioPharma swings to $691,000 net loss in quarter ended September 30, 2026
INBP•Integrated BioPharma reported a $691,000 net loss for the quarter ended September 30, 2026, compared with net income of $123,000 a year earlier. Revenue fell 22% to $9.91 million.
1. Quarterly results
Integrated BioPharma swung to a $691,000 net loss for the quarter ended September 30, 2026, from net income of $123,000 in the year-earlier quarter. Revenue fell 22% year over year to $9.91 million. Its two largest Contract Manufacturing Segment customers accounted for approximately 88% of total revenue, up from 87% a year earlier.
